Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$6.27B
sum of reported positions
Reported positions
833
Changes vs prior quarter
994
141 new · 267 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 299 measured positions in 6 quarters, the typical new or larger position finished −3.3 pts against the S&P 500 and 39% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 1.05M | $146M | 2.3% | |
| 333K | $83.8M | 1.3% | |
| 223K | $76.6M | 1.2% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $6.73B | $6.27B |
| Positions | 959 | 833 |
| Biggest line | — | Intel 2% |
| 957K |
| $74.9M |
| 1.2% |
| 403K | $73M | 1.2% |
| 696K | $71.2M | 1.1% |
| 76K | $70.7M | 1.1% |
| 176K | $69.9M | 1.1% |
| 514K | $69.6M | 1.1% |
| 922K | $68.6M | 1.1% |
| 1.66M | $68.6M | 1.1% |
| 65K | $68.2M | 1.1% |
| 396K | $66.5M | 1.1% |
| 680K | $65.3M | 1.0% |
| 236K | $65.1M | 1.0% |
| 409K | $62M | 1.0% |
| 660K | $60.5M | 1.0% |
| 571K | $59.1M | 0.9% |
| 151K | $54.8M | 0.9% |
| 849K | $54.5M | 0.9% |
| 185K | $54.3M | 0.9% |
| 1.57M | $50.2M | 0.8% |
| 642K | $49.9M | 0.8% |
| 176K | $49.9M | 0.8% |
| 268K | $48.2M | 0.8% |
Global Partners LP (GLP)
4,898 → 9,951 shares (+103%)
Nexxen International (NEXN)
47K → 51K shares (+8%)
Macrogenics (MGNX)
18K → 97K shares (+426%)
Medifast (MED)
42K shares
Phibro Animal Health (PAHC)
27K → 14K shares (−47%)
Watts Water Technologies (WTS)
8,045 → 1,116 shares (−86%)
Voyager Therapeutics (VYGR)
90K → 123K shares (+37%)
Disc Medicine (IRON)
5,808 shares
Caleres (CAL)
29K → 34K shares (+19%)
Postal Realty Trust (PSTL)
27K → 17K shares (−37%)
Assembly Biosciences (ASMB)
14K → 15K shares (+7%)
Huya (HUYA)
359K → 177K shares (−51%)
X4 Pharmaceuticals (XFOR)
103K → 87K shares (−15%)
Neumora Therapeutics (NMRA)
160K → 238K shares (+48%)
Aclaris Therapeutics (ACRS)
40K → 76K shares (+92%)
Chagee Holdings (CHA)
33K shares
Constellium (CSTM)
13K shares
Kronos Worldwide (KRO)
61K → 63K shares (+4%)
Erasca (ERAS)
59K → 22K shares (−63%)
Entrada Therapeutics (TRDA)
54K shares
Saul Centers, Inc. (BFS)
6,717 → 11K shares (+58%)
Omeros (OMER)
93K → 42K shares (−55%)
Elastic N.V. (ESTC)
6,887 shares
Savara (SVRA)
60K → 63K shares (+5%)
Nathans Famous (NATH)
4,000 → 3,800 shares (−5%)
